Bio-Path 2011 net reduction increases to $2.

This year 2010, the business received a one-period grant award totaling $244,479 that was recorded in additional income and that was not similarly matched in 2011. General and administrative expense increased $97,822 in 2011, primarily because of an active plan that commenced in 2011 relating to the Company’s happen to be and participation in industry conferences. Advancement and Research expenditures were lower in 2011 by $58,636, primarily the consequence of lower expenses for drug materials for testing, which a lot more than offset a rise in clinical trial expenditure and expenditure for technology impairment. For the year 2011, the business reported a net reduction per share of $ predicated on 53,844,195 weighted average shares outstanding, in comparison to a net reduction per talk about of $ for the entire year 2010.Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement Arrowhead Research Corporation, a nanomedicine company with advancement programs in RNAi obesity and therapeutics, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, announced they have entered into a Strategic Alliance and Grasp Services Agreement today. These solutions consist of bioinformatics for siRNA design; lead identification, characterization and optimization; along with siRNA synthesis and CMC-related activities. Related StoriesThree out of four customers not covered for evidence-based obesity treatment servicesStressed Latino parents twice as likely to have children with obesityAustralian experts define key features of metabolically healthful obese’With multiple candidates in the clinic addressing an array of indications, data demonstrating the billed power of RNAi as a therapeutic modality are rapidly accumulating,’ stated Dr.